- Home
- AOMR vs MIST Comparison
AOMR vs MIST Comparison
Compare AOMR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | MIST |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.7M | 176.3M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AOMR | MIST |
|---|---|---|
| Price | $8.02 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $11.31 | $8.50 |
| AVG Volume (30 Days) | 66.2K | ★ 1.7M |
| Earning Date | 05-04-2026 | 03-20-2026 |
| Dividend Yield | ★ 15.48% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,653.36 |
| Revenue Next Year | $1.38 | $12.32 |
| P/E Ratio | $4.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.36 | $0.63 |
| 52 Week High | $10.21 | $3.06 |
Technical Indicators
Market Signals| Indicator | AOMR | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 24.45 |
| Support Level | N/A | N/A |
| Resistance Level | $8.91 | $2.01 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).